Cite
[Safety and immunogenicity of cilgavimab-tixagevimab for COVID-19 pre-exposure prophylaxis in immunocompromised patients].
MLA
Fernández-Prada, María, et al. “[Safety and Immunogenicity of Cilgavimab-Tixagevimab for COVID-19 Pre-Exposure Prophylaxis in Immunocompromised Patients].” Medicina Clinica, vol. 160, no. 10, May 2023, pp. 458–59. EBSCOhost, https://doi.org/10.1016/j.medcli.2023.01.005.
APA
Fernández-Prada, M., Pérez-Martín, J. J., & Cienfuegos-González, P. (2023). [Safety and immunogenicity of cilgavimab-tixagevimab for COVID-19 pre-exposure prophylaxis in immunocompromised patients]. Medicina Clinica, 160(10), 458–459. https://doi.org/10.1016/j.medcli.2023.01.005
Chicago
Fernández-Prada, María, Jaime Jesús Pérez-Martín, and Paula Cienfuegos-González. 2023. “[Safety and Immunogenicity of Cilgavimab-Tixagevimab for COVID-19 Pre-Exposure Prophylaxis in Immunocompromised Patients].” Medicina Clinica 160 (10): 458–59. doi:10.1016/j.medcli.2023.01.005.